Stay updated with breaking news from Mutated Advanced. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the gefitinib plus chemotherapy group, with HR 0.58 (significant). 2. The 5-year progression-free survival was 1.71% in the gefitinib group vs 6.67% in the gefitinib plus chemotherapy group, with HR 0.53 (significant). Evidence Rating Level: 1 (Excellent) Study Rundown:
Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.
In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.
Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.
Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.